ACE Technology Guidances

ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 01 Sep 2020
Last Updated on 01 Sep 2020
A- A+
Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has recommended the following antiretroviral therapies (ARTs):
  • Nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs): lamivudine 150 mg tablet, tenofovir disoproxil fumarate 300 mg tablet, zidovudine 100 mg capsule;
  • Non-nucleoside reverse transcriptase inhibitors (NNRTIs): efavirenz 200 mg and 600 mg tablets, etravirine 200 mg tablet, nevirapine 200 mg and 400 mg tablets, rilpivirine 25 mg tablet;
  • Protease inhibitors (PIs): atazanavir 200 mg and 300 mg capsules, darunavir 600 mg and 800 mg tablets, lopinavir 200 mg/ritonavir 50 mg tablet and lopinavir 80 mg/ritonavir 20 mg oral solution, ritonavir 100 mg tablet;
  • Integrase strand transfer inhibitors (INSTIs): dolutegravir 50 mg tablet, raltegravir 400 mg and 600 mg tablets; and
  • Fixed-dose combinations: abacavir 600 mg/lamivudine 300 mg tablet, abacavir 600 mg/dolutegravir 50 mg/lamivudine 300 mg tablet, emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg tablet
in line with their registered indications for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection.

Subsidy status
Raltegravir 400 mg and 600 mg tablets, and emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg tablet are recommended for inclusion on the Medication Assistance Fund (MAF) in combination with other antiretroviral agents for the treatment of HIV-1 infection.

All other abovementioned ARTs are recommended for the inclusion on the MOH Standard Drug List (SDL).

SDL subsidy or MAF assistance do not apply to any other ARTs that are not listed above.

Details of all recommendations are provided in the Annex.

 

Antiretroviral therapies for treating HIV-1 infection (1 Sept 2020)